Coherus Oncology, Inc.CHRSNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank23
3Y CAGR-20.0%
5Y CAGR-6.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-20.0%/yr
vs +18.1%/yr prior
5Y CAGR
-6.3%/yr
Recent deceleration
Acceleration
-38.1pp
Decelerating
Percentile
P23
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $203.97M | -21.9% |
| 2024 | $261.07M | -13.4% |
| 2023 | $301.45M | -24.2% |
| 2022 | $397.84M | -25.3% |
| 2021 | $532.82M | +89.1% |
| 2020 | $281.84M | +21.9% |
| 2019 | $231.22M | +13.1% |
| 2018 | $204.42M | -12.5% |
| 2017 | $233.69M | -23.6% |
| 2016 | $306.04M | - |